Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

On Friday, Stifel analysts revised their price target for Apellis Pharmaceuticals (NASDAQ: APLS) stock, reducing it to $60 from the previous $75, while continuing to support a Buy rating for the ...

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and ...

On Wednesday, Citi analysts adjusted the price target for Apellis Pharmaceuticals (NASDAQ: APLS) shares, reducing it to $41.00 from the previous $49.00 while maintaining a Buy rating. According to ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one ...

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

In other recent news, Apellis Pharmaceuticals reported its first-quarter earnings for 2025, revealing an earnings per share (EPS) of -$0.74, which fell short of the forecasted -$0.34.

Company News Published 01/13/2025, 09:13 AM 0 Apellis reports $709 million in 2024 revenue, plans for growth APLS -5.27% ...

Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with ...